Category: Price Hikes
First published by Matt on July 16, 2020 in the following categories: Consumer Law Industry Latest Price Fixing Price Hikes Pricing and tagged with cma | competition law | investigations | price fixing | pricing
The Competition and Markets Authority (CMA) has been looking into hand sanitiser pricing over concerns that important competition laws may be being breached.
Last month, the CMA announced that they were looking into the matter that is undoubtedly tied to how the use of such products has changed during the ongoing coronavirus pandemic. Although the investigation only started last month, and no assumptions are being made, there have been some significant changes and developments so far.
Clearly, given how the markets for such products has changed over the last few months, this is an important matter that needs to be looked into.
First published by Matt on February 12, 2020 in the following categories: Cartels Latest Price Fixing Price Hikes Pricing and tagged with cartels | cma | competition law | investigations | price fixing | pricing
Here’s the latest news involving the Competition and Markets Authority (CMA) investigation into alleged competition infringements involving Berkshire residential estate agents.
The investigation was launched in early 2018 on the basis that the CMA suspected that there may be infringements of important competition law. In June last year, the CMA issued a formal statement of objections to four estate agents with allegations of breaches, and a settlement was reached with two agents in October. More fines were then issued at the end of last year.
In the often-volatile property market, competition law breaches that leave buyers and sellers paying more simply cannot go unpunished.
The Competition and Markets Authority (CMA) has issued a substantial Fender competition breach fine in the sum of £4.5m.
The fine has been issued almost two years after an investigation into the prominent guitar maker was opened. In its ruling, the CMA has confirmed that Fender has admitted to breaking competition law by restricting prices for UK retailers. The fine that has been issued is therefore subject to the CMA’s leniency and cooperation protocols, which can see penalties reduced.
This is a key ruling given the size of this growing market and the fact that Fender is one of the major players in the sector.
First published by Matt on December 04, 2019 in the following categories: Healthcare Investigations Price Hikes and tagged with cma | competition law | drugs | investigations | Pharmaceuticals | pricing
The UK’s competition regulator has made a provisional finding in the longstanding investigation into drug price hikes, and the outcome is damning.
Issues surrounding pharmaceutical competition breaches are numerous and serious. At the end of the day, the consumer in these cases is patients and the NHS; that’s our tax money.
Any infringement of vital competition laws when it comes to medical matters should always lead to significant punishments, and the work of the CMA (Competition and Markets Authority) in this area is incredibly important. The provisional finding in this matter accompanies an admission from one of the companies involved as well.
First published by Matt on August 12, 2019 in the following categories: Market Sharing Price Fixing Price Hikes Pricing and tagged with cma | competition law | investigations | market abuse | marktet sharing | Pharmaceuticals | price fixing | pricing
In the latest investigation into suspected anti-competitive agreements for pharmaceutical drugs, a statement of objections has been issued by the CMA (Competition and Markets Authority).
The statement was issued last month and relates to a number of pharmaceutical companies who stand accused of participating in anti-competitive behaviour. Whether it’s a case of formal agreements in place, or concerted practices, the issue surrounds the supply of 50mg and 100mg nitrofurantoin capsules in the UK.
This investigation by the CMA into the practices of pharmaceutical firms is one of many that have been ongoing for a number of years. They’re one of the most important areas the CMA needs to safeguard.
First published by Matt on June 13, 2019 in the following categories: Cartels Investigations Price Fixing Price Hikes Pricing and tagged with cartels | cma | competition law | cover bidding | cover pricing | price fixing | pricing
The CMA (Competition and Markets Authority) has secured the disqualification of a number of directors in the aftermath of the fines issued in the office design and fit-out cartel investigation.
In April 2019, fines in the sum of £7m were issued to a number of companies who had been found guilty of breaking vital competition laws. For over a decade, the guilty companies had been engaging in cover bidding, where they were able to artificially inflate the prices of at least 14 contracts. This kind of behaviour can also reduce the quality of services on offer for the consumer as well.
Now, the CMA has taken further action by securing disqualifications for a number of directors who were involved in the cartel activity.
There’s an ongoing groundworks supplier investigation being conducted by the Competition and Markets Authority (CMA), so here’s the latest.
The investigation surrounds suspicions of anti-competitive behaviour in the sector for the supply of groundworks products to the construction industry. The CMA’s investigation is looking into whether any of the key suppliers in the market are breaching important competition laws. If they are found to be acting unethically, they could face substantial fines.
The investigation has been going on for some time now, and a great deal of evidence has been collected and reviewed so far.
First published by Matt on May 30, 2019 in the following categories: Cartels Industry Market Sharing Price Fixing Price Hikes Pricing and tagged with cartels | cma | competition law | market abuse | marktet sharing | Pharmaceuticals | price fixing | pricing
There has been a provisional finding in the pharmaceuticals competition investigation by the Competition and Markets Authority (CMA) who have been looking into companies for quite some time.
It has been alleged that anti-competitive agreements are in place between four firms in the sector, and the calculated costs to the NHS is terrifying. If the provisional finding is formalised, huge fines could be issued to the alleged offenders involved in the investigation.
The costs of anti-competitive arrangements in the pharmaceutical industry often fall on the NHS, and therefore on the taxpayer, which is why these kinds of investigations are incredibly important.
First published by Matt on April 04, 2019 in the following categories: Bid-Rigging Cartels Market Sharing Price Fixing Price Hikes Pricing and tagged with cartels | cma | cover bidding | cover pricing | market abuse | marktet sharing | price fixing | pricing
A huge £7m in total fines has been issued after five companies have admitted to breaches in the office fit-out competition case.
The Competition and Markets Authority (CMA) has been investigating the design, construction and fit-out services market since 2017. In July 2018, they decided to continue their probes, and in March this year, fines have been issued and agreed.
The five companies that have admitted to breaches and will be fined are Coriolis, Fourfront, Loop, Oakley and ThirdWay.
First published by Matt on March 28, 2019 in the following categories: Latest Market Sharing Price Fixing Price Hikes Pricing and tagged with cma | investigations | market abuse | marktet sharing | overpriced medication | Pharmaceuticals | price fixing | pricing
There’s been a provisional finding by the Competition and Markets Authority (CMA) in the important hydrocortisone competition case, with a Statement of Objections issued.
In the coming weeks, the CMA expect written and oral representations to be made following the Statement of Objections that’s been issued.
The provisional findings of the CMA are incredibly worrying. It all comes down whether the two companies at the heart of the investigation colluded in order to charge higher prices and make bigger profits; all at the expense of our NHS, and our hard-earned tax money.